Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785490330> ?p ?o ?g. }
- W2785490330 endingPage "250" @default.
- W2785490330 startingPage "229" @default.
- W2785490330 abstract "Abstract Atherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque instability: In atherothrombosis research, more focus on the contribution of specific risk factors like ectopic fat needs to be considered; definitions of atherothrombosis are important distinguishing different phases of disease, including plaque (in)stability; proteomic and metabolomics data are to be added to genetic information. 2. Circulating cells including platelets and atherothrombosis: Mechanisms of leukocyte and macrophage plasticity, migration, and transformation in murine atherosclerosis need to be considered; disease mechanism-based biomarkers need to be identified; experimental systems are needed that incorporate whole-blood flow to understand how red blood cells influence thrombus formation and stability; knowledge on platelet heterogeneity and priming conditions needs to be translated toward the in vivo situation. 3. Coagulation proteases, fibrin(ogen) and thrombus formation: The role of factor (F) XI in thrombosis including the lower margins of this factor related to safe and effective antithrombotic therapy needs to be established; FXI is a key regulator in linking platelets, thrombin generation, and inflammatory mechanisms in a renin–angiotensin dependent manner; however, the impact on thrombin-dependent PAR signaling needs further study; the fundamental mechanisms in FXIII biology and biochemistry and its impact on thrombus biophysical characteristics need to be explored; the interactions of red cells and fibrin formation and its consequences for thrombus formation and lysis need to be addressed. Platelet–fibrin interactions are pivotal determinants of clot formation and stability with potential therapeutic consequences. 4. Preventive and acute treatment of atherothrombosis and arterial embolism; novel ways and tailoring? The role of protease-activated receptor (PAR)-4 vis à vis PAR-1 as target for antithrombotic therapy merits study; ongoing trials on platelet function test-based antiplatelet therapy adjustment support development of practically feasible tests; risk scores for patients with atrial fibrillation need refinement, taking new biomarkers including coagulation into account; risk scores that consider organ system differences in bleeding may have added value; all forms of oral anticoagulant treatment require better organization, including education and emergency access; laboratory testing still needs rapidly available sensitive tests with short turnaround time. 5. Pleiotropy of coagulation proteases, thrombus resolution and ischaemia–reperfusion: Biobanks specifically for thrombus storage and analysis are needed; further studies on novel modified activated protein C–based agents are required including its cytoprotective properties; new avenues for optimizing treatment of patients with ischaemic stroke are needed, also including novel agents that modify fibrinolytic activity (aimed at plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor." @default.
- W2785490330 created "2018-02-23" @default.
- W2785490330 creator A5004401311 @default.
- W2785490330 creator A5005286957 @default.
- W2785490330 creator A5006545278 @default.
- W2785490330 creator A5008277035 @default.
- W2785490330 creator A5013838935 @default.
- W2785490330 creator A5014139574 @default.
- W2785490330 creator A5014366123 @default.
- W2785490330 creator A5019870857 @default.
- W2785490330 creator A5022419000 @default.
- W2785490330 creator A5022450238 @default.
- W2785490330 creator A5025144397 @default.
- W2785490330 creator A5026353068 @default.
- W2785490330 creator A5026552487 @default.
- W2785490330 creator A5027231306 @default.
- W2785490330 creator A5031168027 @default.
- W2785490330 creator A5034309539 @default.
- W2785490330 creator A5034656290 @default.
- W2785490330 creator A5034822694 @default.
- W2785490330 creator A5037662846 @default.
- W2785490330 creator A5037723133 @default.
- W2785490330 creator A5038271770 @default.
- W2785490330 creator A5038315428 @default.
- W2785490330 creator A5041467461 @default.
- W2785490330 creator A5041800520 @default.
- W2785490330 creator A5042290277 @default.
- W2785490330 creator A5042624694 @default.
- W2785490330 creator A5044822884 @default.
- W2785490330 creator A5045230447 @default.
- W2785490330 creator A5046708642 @default.
- W2785490330 creator A5046773983 @default.
- W2785490330 creator A5047603449 @default.
- W2785490330 creator A5048297907 @default.
- W2785490330 creator A5048593560 @default.
- W2785490330 creator A5050963922 @default.
- W2785490330 creator A5054740178 @default.
- W2785490330 creator A5056501410 @default.
- W2785490330 creator A5057396192 @default.
- W2785490330 creator A5060053979 @default.
- W2785490330 creator A5060794664 @default.
- W2785490330 creator A5062105871 @default.
- W2785490330 creator A5065937818 @default.
- W2785490330 creator A5066840683 @default.
- W2785490330 creator A5068782139 @default.
- W2785490330 creator A5069348426 @default.
- W2785490330 creator A5073188418 @default.
- W2785490330 creator A5074364271 @default.
- W2785490330 creator A5074388972 @default.
- W2785490330 creator A5074883323 @default.
- W2785490330 creator A5075629445 @default.
- W2785490330 creator A5075936484 @default.
- W2785490330 creator A5076076501 @default.
- W2785490330 creator A5077476553 @default.
- W2785490330 creator A5078288985 @default.
- W2785490330 creator A5078686392 @default.
- W2785490330 creator A5080737897 @default.
- W2785490330 creator A5080799654 @default.
- W2785490330 creator A5083177393 @default.
- W2785490330 creator A5084691252 @default.
- W2785490330 creator A5087337437 @default.
- W2785490330 creator A5087630518 @default.
- W2785490330 creator A5089227561 @default.
- W2785490330 creator A5090763481 @default.
- W2785490330 creator A5091734933 @default.
- W2785490330 date "2018-01-01" @default.
- W2785490330 modified "2023-09-27" @default.
- W2785490330 title "Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis" @default.
- W2785490330 cites W105021832 @default.
- W2785490330 cites W144700851 @default.
- W2785490330 cites W1497894124 @default.
- W2785490330 cites W1506314131 @default.
- W2785490330 cites W1507312029 @default.
- W2785490330 cites W1517636809 @default.
- W2785490330 cites W1547546593 @default.
- W2785490330 cites W1570793246 @default.
- W2785490330 cites W1579722187 @default.
- W2785490330 cites W1711208506 @default.
- W2785490330 cites W1747884623 @default.
- W2785490330 cites W1756582968 @default.
- W2785490330 cites W1758704097 @default.
- W2785490330 cites W1762506800 @default.
- W2785490330 cites W1832728002 @default.
- W2785490330 cites W1836026258 @default.
- W2785490330 cites W1856857553 @default.
- W2785490330 cites W1879754864 @default.
- W2785490330 cites W1891694420 @default.
- W2785490330 cites W1898093098 @default.
- W2785490330 cites W1932494896 @default.
- W2785490330 cites W1956305767 @default.
- W2785490330 cites W1964424199 @default.
- W2785490330 cites W1968625689 @default.
- W2785490330 cites W1969297996 @default.
- W2785490330 cites W1969886260 @default.
- W2785490330 cites W1970653879 @default.
- W2785490330 cites W1973485135 @default.
- W2785490330 cites W1977029484 @default.
- W2785490330 cites W1977914106 @default.